Oct 04th 2013 - Edison Investment Research today published a report on Proteome Sciences (PRM.L, LSE:PRM, LON:PRM) entitled "At The Inflection Point". In summary, the report says:
Proteome Sciences made important progress towards becoming profitable. New biomarker assays were launched, including SysQuant and SensiDerm. Its stroke biomarkers were also shown to have promising utility. A new licensing deal was signed with Thermo Fisher Scientific in June. Major PS Biomarker Services contracts and biomarker licensing agreements are expected in the coming year, which are forecast to increase sales by almost threefold in FY13. There is also the prospect of its CK1d drug discovery programme being partnered.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »